introduct
novel
immun
globulin
ig
product
design
provid
protect
respiratori
syncyti
viru
rsv
mediat
respiratori
ill
time
meet
manufactur
requir
establish
fda
antibodi
supplement
immunocompromis
subject
area
cover
review
cover
manufactur
develop
includ
select
plasma
donor
ig
prepar
hightit
antirsv
antibodi
vitro
preclin
data
cotton
rat
model
hispidu
clinic
trial
includ
phase
ii
compassion
use
studi
multicent
pivot
phase
iii
studi
pidd
patient
expert
commentari
data
demonstr
efficaci
prevent
treatment
rsv
preclin
normal
immun
suppress
anim
model
safe
efficaci
treatment
patient
variou
form
primari
immunodefici
diseas
pidd
product
offer
potenti
advantag
avail
ig
prophylaxi
immunocompromis
patient
requir
polyclon
immunoglobulin
supplement
uniqu
antibodi
composit
addit
enhanc
neutral
antirsv
activ
polyclon
ig
composit
preclin
data
support
use
humor
protect
respiratori
pathogen
articl
histori
supplement
immunoglobulin
ig
consid
standard
care
treatment
patient
varieti
antibodi
product
disord
due
b
cell
b
cell
abnorm
collect
refer
primari
immunodefici
diseas
pidd
regular
infus
ig
prevent
vast
major
seriou
bacteri
infect
within
popul
singl
prophylact
regimen
provid
protect
wide
rang
viral
pathogen
patient
suscept
usa
sever
commerci
avail
ig
product
meet
minimum
standard
concentr
antibodi
diphtheria
toxoid
uml
measl
cber
refer
polio
cber
refer
virus
conform
us
fda
guidanc
subpart
j
although
fda
defin
minimum
concentr
antibodi
standard
antibodi
pathogen
import
pidd
patient
requir
titer
antibodi
commerci
polyclon
ig
vari
wide
optim
dose
therapeut
polyclon
intraven
ig
appear
specif
individu
patient
increas
ig
dosag
associ
better
outcom
decreas
incid
infect
even
appropri
ig
therapi
pidd
patient
remain
increas
risk
infect
includ
caus
upper
lower
respiratori
viral
pathogen
includ
rsv
influenza
pidd
patient
patient
secondari
immunodefici
eg
transplant
cancer
etc
high
risk
respiratori
syncyti
viru
rsv
infect
often
result
signific
morbid
mortal
bronchiol
pneumonia
present
prophylact
treatment
avail
rsv
infect
palivizumab
synagi
medimmun
gaithersburg
md
antirsv
monoclon
antibodi
use
confer
season
passiv
immun
shown
effect
prevent
rsvrelat
hospit
particularli
low
birthweight
infant
american
academi
pediatr
aap
recent
revis
recommend
use
guidelin
avail
evid
suggest
use
monoclon
antibodi
rsv
reserv
patient
born
prematur
week
gestat
year
age
current
approv
recommend
treatment
older
age
group
prevent
rsv
diseas
although
treatment
establish
diseas
primarili
support
care
ribavirin
virazol
fdaapprov
treatment
rsv
pulmonari
infect
pediatr
patient
present
efficaci
ribavirin
rsv
treatment
controversi
potenti
signific
side
effect
patient
caregiv
administ
ribavirin
costli
must
administ
hospitalbas
set
ad
cost
context
uncertain
efficaci
altern
therapi
need
polyclon
rsvivig
product
respigam
medimmun
inc
gaithersburg
md
enrich
antibodi
rsv
deriv
plasma
donor
hightit
antirsv
antibodi
previous
avail
approv
indic
palivizumab
voluntarili
withdrawn
us
market
follow
approv
palivizumab
develop
meet
unmet
medic
need
provid
rsv
protect
simultan
supplement
humor
immun
patient
pidd
immun
compromis
state
respigam
market
prevent
rsv
diseas
infant
children
younger
month
chronic
lung
diseas
histori
prematur
birth
hyperimmun
globulin
product
deriv
plasma
pool
hundr
donor
high
neutral
titer
antirsv
antibodi
product
develop
ever
intend
use
pidd
manufactur
specif
adher
fda
standard
collect
plasma
least
one
thousand
donor
test
standard
ig
potenc
requir
product
never
evalu
efficaci
pidd
popul
sever
random
control
trial
demonstr
efficaci
rsvivig
product
prevent
rsv
infect
studi
infant
children
bronchopulmonari
dysplasia
due
congenit
heart
diseas
prematur
mgkg
respigam
reduc
incid
lower
respiratori
tract
infect
vs
control
group
p
hospit
hospit
day
day
intens
care
prevent
studi
random
doubleblind
placebocontrol
multicent
studi
conduct
rsv
season
administr
mg
kg
respigam
everi
day
reduc
incid
hospit
due
rsv
infect
compar
placebo
children
bronchopulmonari
dysplasia
andor
histori
prematur
addit
administr
respigam
prevent
studi
also
reduc
hospit
respiratori
ill
caus
suggest
protect
effect
nonrsvrel
respiratori
tract
infect
addit
post
hoc
analysi
children
groothui
studi
demonstr
statist
signific
decreas
episod
acut
otiti
media
compar
placebo
group
vs
p
follow
immunoprophylaxi
mgkg
respigam
suggest
protect
effect
rsv
enrich
hyperimmun
globulin
may
limit
rsv
alon
respigam
commerci
avail
aap
recommend
state
palivizumab
rsvigiv
immunoprophylaxi
evalu
random
trial
immunocompromis
children
although
specif
recommend
immunocompromis
patient
made
children
sever
immunodefici
eg
sever
combin
immunodefici
sever
acquir
immunodefici
syndrom
may
benefit
immunoprophylaxi
infant
children
receiv
standard
immun
globulin
intraven
igiv
monthli
physician
may
consid
substitut
rsvigiv
rsv
season
recommend
subsequ
clinic
practic
fail
consid
respigam
meet
subpart
j
requir
intend
ensur
appropri
immunoprophylaxi
highrisk
popul
product
avail
numer
publish
report
regard
success
use
respigam
treatment
prevent
rsv
variou
atrisk
immunocompromis
patient
popul
also
report
efficaci
combin
therapi
ribavirin
rsvivig
may
lead
better
outcom
either
product
use
alon
respigam
voluntarili
withdrawn
market
least
part
newli
approv
antirsv
monoclon
antibodi
palivizumab
requir
iv
access
discontinu
respigam
left
void
option
rsv
immunoprophylaxi
particularli
simultan
antirsv
activ
ig
supplement
develop
address
therapeut
void
follow
respigam
discontinu
aqueou
intraven
immun
globulin
prepar
manufactur
pool
plasma
healthi
adult
donor
high
titer
neutral
antirsv
antibodi
time
mean
commerci
ivig
measur
microneutr
assay
product
activ
respigam
shown
compar
cotton
rat
model
vitro
test
unpublish
observ
prepar
use
process
compar
respigam
employ
cohn
oncley
coldalcohol
fraction
solventdeterg
treatment
viral
reduct
step
elimin
envelop
virus
addit
viru
nanofiltr
step
increas
product
safeti
reduc
probabl
transmiss
viral
prion
contamin
part
origin
respigam
manufactur
process
also
includ
manufactur
efficaci
studi
phase
ii
random
doubleblind
placebo
control
trial
immunosuppress
patient
rsv
upper
respiratori
tract
infect
urti
confirm
rtpcr
time
enrol
patient
year
age
receiv
hematopoiet
stem
cell
transplant
solid
organ
transplant
within
year
enrol
treat
studi
drug
patient
treat
concurr
immunosuppress
treatment
exclud
lower
respiratori
tract
infect
lrti
requir
extracorpor
membran
oxygen
cpap
mechan
respiratori
cardiac
support
particip
randomli
assign
treatment
arm
mgkg
follow
mgkg
day
first
administr
highdos
group
mgkg
follow
mgkg
day
first
administr
lowdos
group
placebo
total
patient
patient
per
arm
mean
age
year
sd
enrol
usa
canada
australia
new
zealand
primari
object
phase
ii
studi
defin
dose
produc
fourfold
rise
anti
rsv
neutral
titer
day
compar
baselin
lowdos
group
mean
fold
chang
increas
patient
achiev
rise
titer
mean
fold
chang
observ
placebo
group
highdos
group
met
primari
end
point
mean
fold
chang
circul
titer
patient
achiev
rise
well
toler
studi
drugrel
sae
low
incid
ae
frequent
report
ae
activ
placebo
group
cough
nausea
pyrexia
sinu
congest
diarrhea
platelet
count
decreas
back
pain
signific
differ
ae
rate
two
group
signific
risk
associ
vital
sign
laboratori
assess
physic
exam
identifi
also
evalu
nonrandom
openlabel
compassion
use
studi
usa
australia
new
zealand
collect
data
decemb
februari
compassion
use
request
accept
patient
rsv
lrti
consid
high
risk
mortal
either
fail
standardofcar
therapi
eg
ribivarin
standard
ivig
steroid
etc
altern
therapi
avail
infect
patient
diagnos
rsv
via
rapid
antigen
test
rtpcr
dfa
ifa
viral
cultur
patient
receiv
aerosol
ribavirin
patient
receiv
infus
ivig
palivizumab
steroid
data
collect
patient
receiv
compassion
use
australia
usa
new
zealand
rang
age
month
old
year
median
age
year
patient
less
year
age
nine
patient
male
six
femal
administ
dose
mgkg
follow
addit
dose
mgkg
day
patient
receiv
least
dose
patient
surviv
discharg
hospit
four
patient
die
death
relat
administr
caus
death
includ
respiratori
failur
attribut
rsv
infect
rsv
pneumon
acut
respiratori
distress
asystol
follow
chest
tube
placement
develop
left
pneumothorax
hypox
respiratori
failur
follow
withdraw
care
femal
dual
infect
rsv
complic
acut
influenza
infus
gener
well
toler
compassion
use
experi
three
infus
reaction
note
resolv
upon
complet
infus
decreas
infus
rate
two
patient
experienc
nonseri
ae
respiratori
distress
singl
nonseri
ae
herp
simplex
reactiv
three
ae
consid
relat
unlik
relat
four
sae
document
includ
death
previous
discuss
singl
incid
dyspnea
resolv
prior
discharg
consid
investig
relat
data
collect
trial
limit
repres
small
sampl
size
heterogen
demograph
diseas
characterist
although
inconclus
due
limit
data
sever
trend
observ
compassion
use
studi
possibl
season
variabl
observ
death
occur
within
usa
rsv
season
appar
gender
bia
observ
surviv
appear
impact
underli
condit
includ
oncolog
statu
surviv
appear
influenc
age
higher
mortal
youngest
oldest
patient
consist
potenti
reduc
immun
respons
within
popul
well
gener
fragil
health
importantli
notabl
effect
earli
drug
intervent
surviv
first
patient
requir
ventil
support
surviv
patient
one
five
requir
ventil
support
surviv
adult
year
old
survivor
treat
averag
day
onset
respiratori
symptom
nonsurvivor
treat
day
symptom
onset
similar
trend
observ
pediatr
patient
year
old
survivor
receiv
treatment
earlier
day
nonsurvivor
day
similarli
time
posit
rsv
test
first
treatment
also
shorter
survivor
adult
day
children
day
versu
nonsurvivor
adult
day
children
day
note
associ
signific
increas
rsv
serum
neutral
antibodi
titer
subset
immunocompromis
adult
good
clinic
outcom
enrol
compassion
use
studi
subject
experienc
rise
antirsv
antibodi
titer
compar
baselin
day
posttreat
taken
togeth
data
suggest
earli
intervent
like
import
improv
surviv
trend
observ
compassion
use
studi
consist
previou
report
factor
associ
sever
clinic
cours
increas
mortal
rsv
diseas
although
consid
promis
candid
replac
respigam
patient
rsv
infect
requir
immun
supplement
subject
limit
respigam
pidd
patient
deriv
benefit
ig
use
adma
biolog
inc
develop
address
inconsist
neutral
antirsv
titer
found
commerci
lot
ig
simultan
meet
fda
guidanc
requir
treatment
pidd
patient
defin
subpart
j
addit
standard
respect
minimum
concentr
antibodi
requir
fda
guidanc
manufactur
accord
patent
process
yield
consist
predict
level
neutral
antirsv
antibodi
obtain
plasma
pool
donor
screen
via
valid
microneutr
assay
rsv
found
hyperimmun
rsv
unpublish
observ
princip
differ
deriv
pool
plasma
donor
elev
titer
rsv
deriv
pool
plasma
hightit
donor
plasma
normal
sourc
donor
meet
fda
guidanc
state
treatment
patient
pidd
plasma
pool
need
deriv
minimum
uniqu
donor
studi
conduct
compar
rsv
neutral
antibodi
titer
multipl
lot
titer
singl
avail
lot
overal
averag
ratio
titer
individu
lot
rang
overal
antirsv
titer
observ
studi
consid
equival
ig
product
unpublish
observ
cotton
rat
sigmodon
hispidu
model
rsv
diseas
select
preclin
evalu
wide
use
anim
model
accept
appropri
surrog
predict
efficaci
antirsv
intervent
well
intervent
respiratori
pathogen
includ
parainfluenza
metapneumoviru
influenza
importantli
rsv
infect
hispidu
model
close
mirror
cours
natur
infect
human
respect
immunolog
respons
time
cours
pulmonari
inflammatori
compon
clinic
symptom
hispidu
exhibit
suscept
infect
across
lifespan
use
success
model
rsv
infect
young
elderli
immunosuppress
popul
hispidu
model
previous
demonstr
antirsv
antibodi
titer
provid
standard
ig
prophylaxi
suffici
protect
rsv
diseas
serum
titer
provid
hightit
antirsv
ig
provid
protect
find
consist
result
human
infant
indic
patient
high
titer
matern
acquir
antirsv
antibodi
less
suscept
rsv
diseas
infant
antirsv
serum
antibodi
titer
correl
suggest
model
use
predict
efficaci
immunoprophylaxi
addit
dose
requir
immunoprophylaxi
human
infant
respigam
palivizumab
advanc
clinic
trial
without
need
intermedi
studi
nonhuman
primat
base
data
studi
hispidu
establish
relationship
protect
titer
cotton
rat
vitro
microneutr
assay
human
ivig
elev
antirsv
titer
test
anim
strong
correl
observ
neutral
antibodi
titer
protect
seen
anim
model
human
plasma
donor
success
identifi
donor
contain
hightit
neutral
anti
rsv
ig
use
microneutr
assay
assay
current
use
screen
donor
manufactur
antibodi
composit
character
compar
commerci
lot
ig
sever
vitro
studi
follow
rsv
infect
viral
f
protein
target
palivizumab
mediat
viral
fusion
entri
g
protein
display
antiinflammatori
effect
dampen
host
immun
respons
infect
neutral
antibodi
viral
protein
may
contribut
therapeut
efficaci
microneutr
assay
conduct
quantifi
antig
protein
antif
protein
titer
lot
lot
commerci
ig
unpublish
observ
enhanc
level
antibodi
f
protein
g
protein
greater
compar
commerci
ivig
lot
observ
lot
compar
commerci
ig
suggest
select
donor
base
high
antirsv
titer
microneutr
assay
enhanc
antirsv
antibodi
multipl
rsv
surfac
protein
tabl
previous
report
respigam
administr
prevent
studi
decreas
incid
hospit
lower
respiratori
ill
caus
although
donor
pool
screen
high
antirsv
antibodi
titer
enrich
rsv
antibodi
may
correl
increas
antibodi
titer
respiratori
pathogen
orang
et
al
perform
elisa
evalu
virusspecif
igg
titer
respiratori
virus
produc
plasma
pool
commerci
avail
ivig
lot
repres
brand
tabl
respiratori
virus
test
includ
influenza
b
rsv
parainfluenza
viru
serotyp
hmpv
coronaviru
aggreg
mean
titer
across
virus
higher
observ
commerci
ig
differ
titer
virus
exclud
hmpv
achiev
statist
signific
geometr
mean
ratio
ivig
rang
titer
respiratori
virus
consist
across
lot
virus
test
vari
wide
among
ivig
product
direct
correl
observ
rsv
titer
titer
test
respiratori
virus
pearson
linear
correl
coeffici
rang
log
scale
p
posit
correl
suggest
elev
titer
respiratori
virus
may
consist
featur
lot
protect
efficaci
elev
titer
respiratori
pathogen
rsv
remain
determin
data
support
hypothesi
underli
enhanc
antibodi
titer
nonrsv
virus
number
possibl
consid
possibl
donor
elev
titer
rsv
may
live
area
workplac
expos
long
period
time
mani
respiratori
virus
thu
elev
titer
multipl
respiratori
virus
may
also
possibl
individu
hightit
neutral
antibodi
rsv
immun
respons
gene
encod
elev
antibodi
respons
respiratori
virus
immun
respons
regul
common
histocompat
locu
also
undergon
extens
vitro
preclin
test
cotton
rat
model
summari
studi
provid
tabl
first
prevent
studi
perform
model
either
salin
mgkg
mgkg
mgkg
respigam
administ
intraperiton
five
anim
group
day
prophylaxi
one
day
follow
dose
anim
challeng
pfu
rsva
long
strain
via
intranas
rout
serum
collect
day
anim
euthan
harvest
lung
nasal
tissu
rsv
undetect
lung
anim
receiv
dose
anim
receiv
respigam
viru
undetect
nasal
tissu
anim
receiv
mgkg
quantifi
level
anim
dose
detect
anim
receiv
respigam
antirsv
microneutr
assay
establish
sera
group
reach
neutral
titer
would
consid
protect
human
day
unpublish
observ
experi
establish
efficaci
cotton
rat
model
show
higher
dose
mgkg
requir
steril
nasal
tissu
anim
challeng
rsv
compar
lower
dose
requir
steril
pulmonari
tissu
doserespons
relationship
appar
nasal
infect
neutral
titer
hispidu
sera
intend
util
immunocompromis
popul
cotton
rat
treat
cyclophosphamid
mgkg
day
result
approxim
suppress
white
cell
count
circul
ig
compar
untreat
anim
follow
intranas
infect
rsv
along
strain
bodi
weight
anim
group
treat
dose
day
either
salin
mgkg
dose
mgkg
follow
mgkg
subsequ
dose
control
anim
also
infect
receiv
singl
dose
either
salin
mgkg
mgkg
cyclophosphamid
treat
anim
euthan
day
untreat
anim
euthan
day
effect
reduc
rsv
viral
titer
log
compar
salin
lung
nasal
tissu
treat
normal
immunosuppress
anim
greater
reduct
viral
titer
observ
cyclophosphamid
treat
anim
receiv
higher
dose
rsv
gene
express
measur
qpcr
confirm
system
dissemin
rsv
lung
liver
kidney
well
undetect
rsv
rna
lung
diminish
rna
level
liver
kidney
follow
treatment
studi
pulmonari
histopatholog
immunosuppress
cotton
rat
treat
highdos
approxim
equival
observ
normal
uninfect
rat
unlik
extens
inflammatori
infiltr
observ
lung
salinetr
anim
figur
rsv
neutral
titer
achiev
dose
regimen
would
consid
protect
human
equival
prophylaxi
studi
immunosuppress
cotton
rat
treat
mgkg
mgkg
h
prior
rsv
challeng
show
log
reduct
rsv
viral
titer
lung
homogen
dose
demonstr
singl
dose
prior
exposur
suffici
protect
cotton
rat
infect
also
test
wildtyp
rsva
traci
strain
palivizumabresist
rsva
traci
strain
singleamino
acid
mutat
posit
sinc
polyclon
antibodi
contain
thousand
antibodi
differ
antigen
specif
concentr
specif
never
high
monoclon
singl
specif
reason
higher
dose
polyclon
antibodi
would
administ
compar
monoclon
antibodi
achiev
compar
final
concentr
given
specif
palivizumab
mgkg
reduc
wildtyp
rsva
traci
lung
titer
greater
log
decreas
observ
palivizumabresist
strain
mgkg
reduc
lung
titer
greater
log
wildtyp
palivizumabresist
strain
compar
palivizumab
p
independ
valid
microneutr
assay
establish
mean
rsv
serum
neutral
titer
hispidu
increas
log
follow
prophylaxi
versu
palivizumab
result
confirm
third
laboratori
found
approxim
log
reduct
viral
load
follow
prophylaxi
mgkg
elimin
detect
viru
mgkg
studi
viru
also
elimin
lung
tissu
palivizumab
mgkg
figur
reduct
rsva
long
strain
viral
titer
nasal
tissu
normal
cotton
rat
also
observ
dose
palivizumab
mg
kg
greatest
decreas
achiev
mgkg
activ
influenza
support
vitro
studi
demonstr
neutral
activ
influenza
viru
vivo
data
hispidu
model
show
signific
reduct
influenza
viru
load
lung
influenzainfect
cotton
rat
protect
activ
multipl
influenza
strain
also
investig
hemagglutin
inhibit
assay
hai
hispidu
model
well
establish
protect
unpublish
observ
activ
influenza
correl
hai
inhibit
titer
greater
hai
inhibit
titer
six
lot
measur
influenza
strain
lung
histolog
show
signific
reduct
perivascul
alveol
four
day
infect
anim
treat
compar
salin
influenza
mrna
pulmonari
tissu
pretreat
anim
significantli
reduc
day
day
chemotact
chemokin
mrna
includ
ifngammainduc
protein
rant
reduc
pulmonari
tissu
treat
anim
suggest
inflamm
induc
infect
prevent
markedli
attenu
openlabel
phase
clinic
trial
conduct
evalu
efficaci
safeti
pharmacokinet
subject
pidd
subject
given
intraven
infus
dose
mgkg
everi
week
base
prestudi
infus
schedul
approxim
year
infus
rate
start
mgkgmin
increment
increas
everi
min
maximum
mgkgmin
dose
adjust
maintain
trough
igg
concentr
mgdl
permit
throughout
studi
mean
dose
administ
mgkg
rang
mgkg
infus
administ
maximum
rate
subject
year
age
inclus
confirm
diagnosi
pidd
receiv
stabl
dose
ivig
chang
mean
mgkg
dose
everi
normalsalin
week
month
subject
exclud
histori
advers
reaction
bloodderiv
product
select
iga
defici
ige
antiiga
abnorm
liver
function
histori
deep
vein
thrombosi
hemolysi
posit
coomb
test
current
pregnanc
lactat
subject
male
femal
mean
year
sinc
diagnosi
averag
age
year
enrol
subject
receiv
least
one
dose
includ
safeti
popul
demograph
data
compar
three
four
week
dose
schedul
subject
primari
efficaci
end
point
studi
acut
seriou
bacteri
infect
asbi
rate
treatment
period
consist
fda
recommend
asbi
rate
less
infect
per
personyear
consid
efficaci
subject
year
zero
asbi
observ
secondari
end
point
includ
incid
infect
kind
infect
per
subject
per
year
number
day
lost
workschoolusu
activ
due
infect
day
per
subject
per
year
unschedul
visit
physician
er
due
infect
visit
per
subject
per
year
hospit
due
infect
hospit
per
subject
per
year
number
day
antibiot
therapi
day
per
subject
per
year
summari
clinic
efficaci
data
provid
tabl
taken
togeth
data
attest
efficaci
prevent
seriou
infect
minim
unschedul
medic
visit
hospit
pidd
popul
overal
well
toler
met
target
proport
studi
infus
tempor
associ
advers
event
taae
overal
subject
experienc
taae
infus
treatment
emerg
ae
document
subject
studi
teae
subject
record
relat
studi
drug
frequent
report
ae
unrel
studi
drug
headach
sinus
diarrhea
viral
gastroenter
nasopharyng
urti
headach
frequent
studi
drugrel
seriou
advers
event
sae
report
although
two
sae
postop
wound
infect
migrain
document
advers
infus
reaction
subject
infus
report
headach
myalgia
frequent
four
infus
site
reaction
two
subject
also
document
infus
site
extravas
pain
summari
clinic
safeti
present
tabl
relationship
dose
trough
level
risk
seriou
nonseri
infect
well
total
trough
igg
specif
antibodi
level
also
investig
pharmacokinet
sampl
perform
subset
patient
begin
infus
ensur
washout
previou
ig
product
administr
treatment
interv
result
increas
specif
antibodi
cmv
tetanu
hib
measl
rsv
pneumonia
figur
show
profil
antirsv
antibodi
follow
infus
maintain
throughout
dose
interv
expect
greatest
increas
observ
rsv
neutral
antibodi
postinfus
mean
ci
fold
chang
baselin
c
max
baselin
overal
fold
chang
dose
mgkg
mgkg
respect
appar
differ
observ
dose
interv
mean
igg
concentr
c
max
sex
age
effect
igg
pharmacokinet
biolog
licens
applic
bla
file
fda
center
biolog
evalu
research
cber
adma
biolog
also
file
unit
state
patent
entitl
composit
method
treatment
immunodefici
patent
cover
adma
method
produc
pool
plasma
contain
elev
rsv
neutral
antibodi
antibodi
direct
one
respiratori
pathogen
process
includ
assay
screen
donor
high
rsv
neutral
titer
select
highest
assay
donor
donor
ig
fraction
neutral
titer
pool
plasma
donor
select
previou
step
cold
alcohol
fraction
process
purif
finish
product
previous
discuss
process
outlin
patent
ensur
consist
product
lottolot
antirsv
neutral
titer
least
twofold
higher
control
ig
product
enhanc
bind
activ
rsv
respiratori
virus
predecessor
novel
immun
globulin
manufactur
use
uniqu
approach
meet
specif
criteria
plasma
donor
select
plasma
pool
formul
respigam
previou
hyperimmun
globulin
product
enrich
antirsv
activ
longer
market
sever
reason
includ
approv
monoclon
antirsv
antibodi
palivizumab
although
demonstr
efficaci
prevent
rsv
infect
number
limit
administr
indic
sole
therapi
immun
supplement
pidd
popul
although
palivizumab
current
commerci
avail
therapeut
option
patient
requir
prophylaxi
rsv
monoclon
antibodi
provid
immun
reconstitut
pidd
populationlik
polyclon
product
potenti
provid
protect
respiratori
virus
palivizumabresist
strain
rsv
becom
preval
addit
polyclon
antibodi
advantag
provid
antiinflammatori
activ
trigger
rsv
monoclon
develop
adma
biolog
fill
void
left
market
withdraw
respigam
well
toler
phase
ii
trial
immunocompromis
patient
rsv
urti
achiev
primari
efficaci
end
point
mean
fold
chang
circul
rsv
neutral
titer
patient
highdos
arm
openlabel
compassion
use
treatment
studi
conduct
patient
rsv
lrti
high
risk
mortal
surviv
although
conclus
drawn
due
limit
sampl
size
sever
encourag
trend
toward
improv
clinic
outcom
observ
factor
associ
surviv
includ
age
earli
intervent
absenc
need
ventil
support
patient
fewer
averag
day
onset
respiratori
symptom
first
treatment
shorter
time
posit
rsv
test
first
treatment
also
associ
signific
increas
rsv
serum
neutral
antibodi
titer
subset
immunocompromis
adult
favor
clinic
outcom
enrol
compassion
use
studi
although
promis
efficaci
safeti
perspect
subject
limit
respigam
meet
fda
requir
supplement
pidd
popul
current
regulatori
review
manufactur
use
novel
approach
pool
plasma
donor
exhibit
antirsv
neutral
antibodi
titer
comparison
titer
unpublish
observ
meet
fda
ig
supplement
requir
minimum
titer
antibodi
diphtheria
toxoid
measl
polio
virus
immunocompromis
popul
includ
pidd
patient
compani
also
antirsv
potenc
test
manufactur
standard
perform
batch
although
yet
approv
comprehens
evalu
preclin
clinic
data
collect
suggest
may
provid
import
option
patient
benefit
ig
supplement
risk
viralinduc
respiratori
ill
microneutr
assay
conduct
quantifi
igg
titer
rsv
surfac
protein
f
protein
g
protein
demonstr
manufactur
process
select
substanti
higher
antirsv
antibodi
titer
multipl
rsv
antigen
compar
commerci
avail
ig
product
enrich
limit
rsv
also
yield
consist
higher
higher
aggreg
mean
neutral
titer
host
respiratori
pathogen
includ
influenza
b
parainfluenza
viru
serotyp
hmpv
coronaviru
although
prophylact
efficaci
human
popul
addit
pathogen
yet
establish
probabl
may
impact
incid
respiratori
infect
caus
within
immunocompromis
popul
similar
trend
observ
respigam
prevent
studi
serum
hispidu
anim
test
strain
influenza
hai
inhibit
assay
consid
protect
preval
circul
strain
titer
rang
similar
protect
observ
noncircul
influenza
strain
suggest
donor
select
process
use
manufactur
enrich
humor
antibodi
common
respiratori
pathogen
donor
expos
hispidu
challeng
influenzaa
california
one
day
follow
prophylact
administr
mgkg
significantli
improv
lung
histolog
reduc
viral
mrna
pulmonari
tissu
reduc
chemotact
chemokin
rant
mrna
compar
salinetr
anim
suggest
observ
titer
may
adequ
provid
improv
protect
circul
influenza
strain
hispidu
model
administ
intraperiton
dose
mgkg
mgkg
mgkg
prior
challeng
prevent
rsv
diseas
healthi
young
anim
rsv
undetect
lung
anim
dose
nasal
tissu
anim
receiv
mgkg
neutral
titer
would
consid
protect
human
treatment
set
hispidu
immunosuppress
cyclophosphamid
approxim
log
reduct
rsv
viral
titer
lung
nasal
tissu
compar
salinetr
anim
importantli
pulmonari
histopatholog
immunosuppress
anim
treat
mgkg
similar
histopatholog
normal
uninfect
anim
prophylaxi
studi
immunosuppress
anim
singl
dose
suffici
protect
anim
infect
openlabel
phase
iii
clinic
trial
conduct
evalu
efficaci
safeti
pharmacokinet
subject
pidd
provid
strong
evid
regard
efficaci
product
viral
respiratori
pathogen
seriou
bacteri
infect
pidd
patient
overal
well
toler
patient
advers
event
sae
relat
studi
drug
met
primari
efficaci
end
point
studi
achiev
asbi
rate
less
infect
per
personyear
asbi
observ
approxim
subjectyear
secondari
end
point
also
support
efficaci
infect
low
incid
infect
kind
day
lost
usual
activ
unschedul
medic
visit
hospit
due
infect
day
antibiot
therapi
clinic
outcom
correl
elev
igg
antibodi
cmv
tetanu
measl
pneumonia
anticip
donor
screen
method
use
manufactur
greatest
increas
observ
postinfus
mean
titer
rsv
neutral
antibodi
magnitud
chang
depend
dose
clear
confer
passiv
immun
bacteri
infect
respiratori
virus
includ
rsv
prophylact
efficaci
respiratori
virus
human
yet
establish
gap
therapeut
option
immun
globulin
supplement
pidd
patient
high
risk
viral
respiratori
infect
preclin
clinic
data
collect
support
use
product
popul
avail
option
commerci
ig
product
standard
pathogen
common
within
popul
approv
base
reduct
incid
asbi
extend
coverag
product
includ
rsv
possibl
respiratori
virus
commonli
acquir
patient
high
risk
rsv
diseas
broad
rang
protect
provid
suggest
import
agent
supplement
physician
arsen
immunocompromis
patient
rsv
season
patient
might
benefit
broad
coverag
product
previou
aap
recommend
use
respigam
replac
commerci
ig
product
immunocompromis
children
rsv
season
take
standard
respigam
account
respigam
appropri
indic
use
popul
without
addit
supplement
may
uniqu
pois
fill
therapeut
role
data
collect
hispidu
model
multipl
agent
proven
reliabl
predict
efficaci
new
therapeut
agent
rsv
importantli
model
extend
young
elderli
immunosuppress
popul
achiev
protect
titer
hispidu
protect
anim
infect
success
maintain
normal
lung
histolog
elimin
infect
treat
anim
find
extend
immunocompromis
anim
anim
infect
palivizumabresist
rsv
data
collect
hispidu
similar
trend
observ
phase
ii
compassion
use
studi
provid
equival
antirsv
neutral
titer
compar
neutral
titer
reach
anim
model
averag
twofold
higher
achiev
clinic
dose
regimen
palivizumab
although
limit
size
studi
demonstr
achiev
high
rsv
neutral
antibodi
titer
consid
protect
human
could
result
improv
outcom
rsvinfect
patient
treatment
begin
soon
onset
symptom
importantli
meet
ig
antibodi
standard
requir
phase
iii
primari
efficaci
end
point
zero
seriou
bacteri
infect
observ
personyear
therefor
suitabl
use
supplement
pidd
patient
addit
reduct
incid
seriou
bacteri
infect
rsv
neutral
antibodi
titer
respiratori
pathogen
also
elev
hispidu
achiev
protect
titer
four
strain
commonli
circul
influenza
improv
lung
histolog
postinfect
reduc
elimin
influenza
viral
mrna
suppress
chemotact
signal
taken
togeth
data
suggest
compar
effect
possibl
human
although
remain
determin
process
enrich
antirsv
antibodi
within
donor
pool
strongli
correl
increas
antibodi
titer
respiratori
virus
find
reproduc
lot
test
impact
increas
humor
protect
rang
commonli
circul
respiratori
virus
pose
risk
pidd
patient
yet
known
although
consist
supplement
ig
respiratori
ill
like
clinic
benefit
base
previou
data
gener
prevent
studi
group
potenti
redefin
treatment
within
immunocompromis
popul
vaccin
often
ineffect
commonli
use
prophylact
agent
provid
protect
limit
spectrum
specif
pathogen
potenti
broadspectrum
protect
respiratori
virus
previous
requir
addit
prophylact
agent
protect
agent
avail
invalu
physician
seek
optim
protect
patient
enhanc
passiv
immun
rang
commonli
encount
pathogen
virus
addit
patient
could
use
patient
hospit
sever
rsv
respiratori
infect
respond
convent
therapi
observ
correl
select
donor
hightit
rsv
neutral
antibodi
elev
antibodi
titer
commonli
circul
virus
may
pave
way
addit
ig
product
expand
coverag
singl
prophylact
option
rsv
current
market
product
previous
develop
provid
rsv
prophylact
activ
meet
minimum
fda
requir
antibodi
standard
use
ig
supplement
pidd
patient
immun
globulin
product
manufactur
pool
plasma
donor
elev
rsv
neutral
titer
well
toler
phase
ii
studi
achiev
foldchang
circul
rsv
neutral
titer
patient
dose
mgkg
openlabel
compassion
use
studi
also
conduct
suggest
may
provid
surviv
benefit
subject
particularli
treatment
initi
earli
current
develop
manufactur
use
pool
plasma
donor
highest
titer
antirsv
neutral
antibodi
comparison
standard
equival
antirsv
titer
use
proprietari
standard
meet
fda
immunoglobulin
supplement
requir
minimum
titer
antibodi
diphtheria
toxoid
measl
polio
virus
immunocompromis
popul
includ
pidd
patient
manufactur
process
select
higher
titer
antirsv
antibodi
multipl
rsv
antigen
compar
commerci
avail
ig
product
select
also
yield
consist
higher
higher
aggreg
mean
neutral
antibodi
titer
respiratori
pathogen
evid
hispidu
preclin
test
demonstr
effect
rsv
treatment
prophylaxi
normal
immunocompromis
host
also
show
efficaci
commonli
circul
strain
influenza
protect
palivizumabresist
rsv
probabl
contain
antibodi
target
multipl
rsv
surfac
protein
well
toler
phase
iii
clinic
trial
met
primari
efficaci
endpoint
seriou
bacteri
infect
per
person
year
seriou
bacteri
infect
document
personyear
addit
inform
regard
statu
found
adma
biolog
inc
websit
http
wwwadmabiologicscom
articl
fund
adma
biolog
inc
bn
greener
employe
ppd
inc
adma
biolog
inc
contract
ppd
inc
provid
editori
assist
prepar
manuscript
j
mond
chief
medic
scientif
offic
adma
biolog
inc
author
relev
affili
financi
involv
organ
entiti
financi
interest
financi
conflict
subject
matter
materi
discuss
manuscript
apart
disclos
peer
review
manuscript
relev
financi
relationship
disclos
